Arcutis Biotherapeutics, Inc. Stock Price, News & Analysis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the completion of a public offering of 4,000,000 shares at $25.00 per share, raising gross proceeds of $100 million. Additionally, a private placement of 1,400,000 shares was made to OrbiMed Advisors, generating another $35 million. The offering's registration statement became effective on October 1, 2020. Goldman Sachs, Cowen, and Guggenheim are managing the public offering. Arcutis focuses on developing treatments for immune-mediated dermatological diseases, with its lead candidate targeting plaque psoriasis and other skin conditions.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced a public offering of 4,000,000 shares at $25.00 each, aiming for gross proceeds of $100 million. The offering includes a 30-day option for underwriters to purchase an additional 600,000 shares. Concurrently, Arcutis plans a private placement of 1,400,000 shares at the same price for gross proceeds of $35 million, contingent on the public offering's success. The public offering is expected to close on October 6, 2020. The company focuses on immuno-dermatology treatments and has a developing pipeline of therapies.

Arcutis Biotherapeutics (Nasdaq: ARQT) has completed enrollment in two pivotal Phase 3 trials (DERMIS-1 and DERMIS-2) for its topical roflumilast cream, a potential treatment for plaque psoriasis affecting about 8.6 million patients in the U.S. Topline results are expected in Q1 2021, with a New Drug Application (NDA) submission planned by year-end. Previous Phase 2 studies indicated significant improvements and a favorable safety profile for roflumilast. The cream's unique formulation aims to provide effective treatment without the trade-offs seen in existing therapies.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2020. The fireside chat presentation is scheduled for September 17, 2020, at 7:40 a.m. PT / 10:40 a.m. ET. This event focuses on the company’s developments in immune-mediated dermatological diseases. Interested parties can access the webcast through the company’s website, which will be available for replay for 30 days following the conference. Arcutis is committed to addressing unmet needs with its innovative therapies for dermatological conditions.

Arcutis Biotherapeutics has announced the advancement of its topical roflumilast cream to Phase 3 clinical trials for atopic dermatitis without conducting a Phase 2b trial following FDA discussions. Roflumilast cream, a selective PDE4 inhibitor, aims to offer a once-daily treatment option for approximately 20 million U.S. patients. Previous trials indicated its efficacy and tolerability are comparable to existing treatments. Topline data for plaque psoriasis trials is expected in early 2021, marking a significant step in developing innovative therapies for dermatological conditions.

Arcutis Biotherapeutics (Nasdaq: ARQT) reported its Q2 2020 financial results, revealing a strong cash position of $224 million. The company anticipates six key clinical data readouts, including pivotal Phase 3 trials for topical roflumilast cream for plaque psoriasis by 2021. R&D expenses surged to $30 million, compared to $7.2 million last year, reflecting ongoing clinical trials. The net loss for Q2 was $35.4 million, or $0.94 per share. Despite rising losses, the firm remains focused on addressing dermatological diseases affecting over 20 million U.S. patients.

Arcutis Biotherapeutics (Nasdaq: ARQT) will participate in the Wedbush PacGrow Healthcare Conference on August 12, 2020, at 10:10 a.m. PT / 1:10 p.m. ET. The presentation will be available via webcast on Arcutis' website, with an archived replay accessible for 30 days post-conference. Arcutis focuses on developing treatments for immune-mediated dermatological diseases, using advancements in immunology to tackle significant challenges. Their lead candidate, topical roflumilast, aims to improve care for conditions like plaque psoriasis and atopic dermatitis.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced positive results from a Phase 1/2a trial of its topical roflumilast cream for chronic plaque psoriasis. The cream demonstrated safety and efficacy at 0.5% and 0.15% doses, indicating a potential new treatment option. According to the study, 66%-67% improvement was observed at week 4 versus 38% for the vehicle. Roflumilast cream showed favorable tolerability, with no patient discontinuations due to adverse events. Arcutis plans to release Phase 3 topline data in H1 2021, further solidifying its position in the dermatological treatment market.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced positive results from a Phase 2b trial of its topical roflumilast cream for chronic plaque psoriasis, published in The New England Journal of Medicine. The study demonstrated a significant improvement in psoriasis symptoms, with 28% of patients achieving clear or almost clear skin at week six. Roflumilast cream was well-tolerated, with adverse events primarily mild. The company is conducting Phase 3 trials, with topline data expected in early 2021, marking a potential breakthrough for patients needing new treatment options.